Two new oncology tests — classifying metastatic cancer and identifying patients with estrogen receptor positive (ER+) breast cancer who are at high risk of recurrence as well as unlikely to respond favorably to standard adjuvant endocrine therapy — from AviaraDx, Inc. are now state-approved in New York.

The tests, based on proprietary AviaraDx molecular technologies, are New York state-approved and available through the company’s CAP-certified CLIA laboratory. Both can utilize small formalin-fixed and paraffin-embedded (FFPE) tissue samples easily available from imaging-guided needle biopsies.

CancerTYPE ID™ and H/I™ (HOXB13/IL17BR) are the two said tests from AviaraDx, Inc.

Read here to find out more.

[Thanks to Laura Baumgartner for the hat tip!]

Post from: Blisstree

AviaraDx: New Molecular Oncology Test for Metastatic & Breast Cancer